Atrium Therapeutics Inc 2026年季度报告

Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.Yes☐No☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growthcompany☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 5, 2026, the registrant had 17,105,643 shares of common stock, $0.001 par value per share, outstanding. Cautionary Statement Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements about us that involve substantialrisks and uncertainties. All statements other than statements of historical facts contained in this information statement, includingstatements regarding our plans, objectives, goals, strategies, future events, financing needs, plans or intentions relating to productcandidates and markets and business trends, are forward-looking statements. In some cases, you can identify forward-looking statementsby words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “possible,”“potential,” “predict,” “project,” “design,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or othercomparable terminology. These forward-looking statements include, but are not limited to, statements about: •the initiation, timing, progress, potential registrational quality, and results of our research and development programs,preclinical studies, any clinical trials, investigational new drug ("IND"), and other regulatory submissions;•the beneficial characteristics, including potential safety, efficacy and therapeutic effects of our product candidates and thepotential advantages of our product candidates compared to alternative therapies;•the success and capabilities of the ribonucleic acid ("RNA") delivery platform;•the prevalence of certain diseases and conditions we intend to treat and our estimates of the potential market opportunity forour product candidates;•the number of patients that we will enroll in our clinical trials;•the timing of and costs involved in obtaining and maintaining regulatory approval of our current product candidates and anyfuture product candidates that we may identify or develop;•our ability to meet future regulatory standards with respect to our product candidates, if approved;•our plans relating to the further development and manufacturing of our product candidates, including for additional indicationsthat we may pursue;•the rate and degree of market acceptance and therapeutic benefits of our product candidates, if approved;•our ability to develop or partner and progress our current and future product candidates;•the implementation of our strategic plans for our business, product candidates, research programs and technologies;•the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;•anticipated developments related to our competitors and our industry;•our competitive position and the success of competing therapies that are or may become available;•our ability to maintain our current license agreements and collaborations and identify and enter into future license agreementsand collaborations;•the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators withdevelopment, regulatory, manufacturing or commercialization expertise;•our reliance on third parties to conduct preclinical studies and clinical trials of our product candidates;•our ability to efficiently and cost-effectively conduct our current and future clinical trials;•our reliance on third parties for the manufacture of our product candidates;•our plan